Delaware’s PBC Sale-Process Ruling Rewrites Revlon for Purpose-Driven Companies—and Deal Lawyers Need a New Playbook

The Chancery Court Draws a Line Between Profit and Purpose

For three decades, Revlon, Inc. v. MacAndrews & Forbes Holdings, Inc., 506 A.2d 173 (Del. 1986), has stood for an unyielding proposition: when a Delaware corporation sells itself for cash, the board's singular duty is to maximize stockholder value. Full stop. But on July 29, 2026, the Delaware Court of Chancery carved out a significant exception, ruling that public benefit corporations are not legally required to maximize stock price in a sale the same way traditional corporations are, because PBC law demands that directors balance pecuniary value against the company's stated public benefit purpose.

The ruling is the first authoritative interpretation of how 8 Del. C. § 362—Delaware's public benefit corporation statute—interacts with enhanced scrutiny under Revlon. And it matters enormously for the growing cohort of PBCs contemplating exits.

What the Statute Actually Says

Section 362(a) requires a PBC board to "manage or direct the business and affairs of the public benefit corporation in a manner that balances the pecuniary interests of the stockholders, the best interests of those materially affected by the corporation's conduct, and the specific public benefit or public benefits identified in its certificate of incorporation." That is a tripartite mandate—qualitatively different from the stockholder-primacy framework that governs traditional corporations under Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985), and its progeny.

The Chancery Court's ruling confirms what sophisticated PBC counsel have long argued: the word "balances" in § 362 is not surplusage. It means something. And what it means is that a PBC board facing a cash-out merger can legitimately weigh whether the buyer will honor the company's social mission—not merely whether the price is the highest available.

The Practical Earthquake for M&A Practice

Here's why deal lawyers should care. Under traditional Revlon analysis, a board that accepts a lower bid because of non-price considerations invites near-certain liability. The entire architecture of Delaware sale-process jurisprudence—from Smith v. Van Gorkom, 488 A.2d 858 (Del. 1985), through the modern Corwin-era framework—presumes that price maximization is the lodestar once a company is in play.

The PBC ruling disrupts that presumption. A benefit corporation board can now point to § 362 and argue, credibly, that accepting a $45-per-share bid from a buyer committed to preserving the company's environmental mission may satisfy its fiduciary obligations even when a $48-per-share bid from a private equity acquirer is on the table. That is a genuinely novel doctrinal position.

The ruling does not give PBC boards carte blanche. It gives them discretion—bounded, articulable, and subject to enhanced scrutiny—but discretion nonetheless.

But the discretion is not unlimited. The court's reasoning suggests that PBC directors must still demonstrate a rational connection between the chosen transaction and the corporation's stated public benefit. A board cannot simply invoke "purpose" as a talisman to justify entrenchment or self-dealing. The record must show genuine balancing.

Interaction with SB 21 and the Broader Delaware Landscape

This ruling arrives at a moment when Delaware corporate law is in flux. The Delaware Supreme Court's February 2026 decision upholding SB 21—the 2025 legislative overhaul that limits certain stockholder suits when a deal is approved by an independent committee or by public shareholders—has already recalibrated the litigation risk calculus for conflicted transactions. The PBC sale-process ruling adds another variable.

For PBCs, the combination is potent. A benefit corporation that structures its sale with an independent special committee and articulates a clear § 362 balancing rationale may now enjoy something approaching business judgment rule protection for decisions that would have been per se breaches under traditional Revlon analysis.

Meanwhile, the pending Silver Lake/Endeavor appraisal dispute—where Silver Lake is asking the Chancery Court to bar appraisal claims by hedge funds that bought stock post-announcement—underscores that Delaware's courts remain the epicenter of M&A litigation innovation. The PBC ruling will inevitably intersect with appraisal strategy. If a PBC accepts a below-market bid for mission-related reasons, dissenting stockholders may argue that the "fair value" of their shares under 8 Del. C. § 262 should reflect the higher rejected offer. How the Chancery Court handles that argument will be the next frontier.

What Practitioners Should Do Now

For PBC boards contemplating a sale: Build the record early. Document the specific public benefit identified in your charter, the board's deliberations about how each bidder would affect that benefit, and the balancing analysis. Conclusory statements about "purpose" will not survive enhanced scrutiny.

For acquirers of PBCs: Due diligence must now include a thorough review of the target's § 362 obligations and any board minutes reflecting mission-related deliberations. A merger agreement that ignores the PBC's stated benefit invites post-closing litigation.

For traditional corporations considering PBC conversion: Understand that conversion is not merely branding. It fundamentally alters the fiduciary framework that will govern your eventual exit. The days of treating PBC status as a marketing exercise are over.

The Chancery Court has spoken: purpose is not just permissible in a sale process—it is legally required for PBCs. That is a paradigm shift, and the deal lawyers who internalize it first will have a decisive advantage.